Participant Flow

Out patient department screening

• 300 patients

Patients eligible

• 150 patients

Patients recruited post consent

48 patients in each group= total 96 patients

Baseline Characteristics:

Correlation of clinical parameters between SLET and CLET groups using Fisher's exact test.

Clinical Parameters	SLET	CLET	p value
Age	20.2 ± 13.1	22.4 ± 14.5	0.363
Gender			p = 0.999
- Male - Female	40 (83.3%)	29 (60.4%)	0.013*
	8 (16.6%)	19 (39.9%)	
Eye			
- Right	26 (54.%)	28 (58.3%)	0.837
- Left	22 (45.8%)	20 (41.7%)	
Cause of Injury	31 (64.6%)	32 (66.7%)	
- Alkali	4 (8.3%)	5 (10.4%)	
AcidThermalBlastOthers	3 (6.3%)	3 (6.3%)	0.999
	5 (10.4%)	4 (8.3%)	
	5 (10.4%)	4 (8.3%)	
Duration from injury to Surgery			
(median)	18 (6- 264)	12(5-268)	0.06
Symblepharon	17 (35.4%)	16 (33.3%)	
- Nil	17 (35.4%)	11 (22.9%)	
 Only till conjunctiva Symblepheron extending to cornea 	3 (6.2%)	7 (14.6%)	0.367
- Full Symblephera	11 (22.9%)	14 (29.2%)	
LSCD			
- <270° LSCD	8 (16.7%)	6 (12.5%)	0.773
- 270° to 360° LSCD	40 (83.3%)	42 (87.5%)	J J
Total Follow up			
(mean ± SD)			

Outcome Measures:

Correlation of postoperative BCVA between SLET and CLET operated eyes at 3 months, 6 months, 6months, 1 year, 2 year, 3 year and last follow up using Friedman's test (skewed data) followed by Wilcoxon signed value.

BCVA Outcomes	SLET	CLET	p value
Preoperative BCVA	2.33 ± 0.5	2.28 ± 1.48	0.597
Post op VA (3 months)	$0.89 \pm 0.2^*$	$0.97 \pm 0.39^*$	0.420
Post op VA (6 months)	$0.70 \pm 0.20^*$	$0.83 \pm 0.38^*$	0.039
Post op VA (1 year)	0.52 ± 0.18*	0.71 ± 0.40*	0.0001
Post op VA (2 year)	$0.43 \pm 0.15^*$	0.67 ± 0.41*	0.0001
Post op VA (3 year)	0.37 ± 0.18*	$0.62 \pm 0.42^*$	0.0001
Post op VA (last follow up)	0.35 ± 0.19*	0.56 ± 0.42*	0.0001

^{*}Shows significant BCVA improvement from baseline preoperative BCVA in respective SLET and CLET groups




Figure: Correlation of postoperative BCVA between SLET and CLET operated eyes at 3 months, 6 months, 6 months, 1 year, 2 year, 3 year and last follow up.

Adverse events:

There were no adverse events in our study